- Home
- FGI vs MBRX Comparison
FGI vs MBRX Comparison
Compare FGI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FGI | MBRX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | 420 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | FGI | MBRX |
|---|---|---|
| Price | $3.80 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 8.4K | ★ 229.4K |
| Earning Date | 03-24-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.25 |
| 52 Week High | $12.62 | $7.98 |
Technical Indicators
Market Signals| Indicator | FGI | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 33.10 |
| Support Level | $3.24 | $0.37 |
| Resistance Level | $4.42 | $5.22 |
| Average True Range (ATR) | 0.44 | 0.15 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 13.78 | 42.62 |
Price Performance
Historical ComparisonAbout FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.